Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Metformin / pioglitazone price, strengths & recalls

Pharmacies pay $8.82 for 30 tablets of Metformin / pioglitazone 500 mg / 15 mg tablet this week, and from $6.25 to $8.82 across its 2 priced strengths and forms. 4 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on September 11, 2026.

Generic
Pharmacies pay$8.82for 30 tablets of 500 mg / 15 mg tablet+3.7% in 4 weeks
Fair cash price
$20.64
Strengths
2
Makers
4
Updated
Nov 11

Metformin / pioglitazone price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
500 mg / 15 mg tablet$0.2940$8.82 / 30 tablets+3.7%-34.1%
850 mg / 15 mg tablet$0.2083$6.25 / 30 tablets-12.9%-27.7%

Supply status: shortages & recalls

No shortage reportedChecked Nov 17, 2026
No ongoing recalls1 recall on record, latest Feb 12, 2020

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for metformin / pioglitazone? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedSeptember 11, 2026
Version15 of 14
EffectiveSep 2, 2026
Read the label

These highlights do not include all the information needed to use PIOGLITAZONE AND METFORMIN HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PIOGLITAZONE AND METFORMIN HYDROCHLORIDE TABLETS. PIOGLITAZONE and METFORMIN HYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 2005

This drug has a boxed warning

WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS

Congestive Heart Failure

Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1)].

After initiation of pioglitazone and metformin hydrochloride, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If congestive heart failure develops while taking pioglitazone and metformin hydrochloride, consider discontinuation of pioglitazone and metformin hydrochloride or dosage reduction of pioglitazone in pioglitazone and metformin hydrochloride [see Warnings and Precautions (5.1)].

Pioglitazone and metformin hydrochloride is not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1)].

Initiation of pioglitazone and metformin hydrochloride in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4), Warnings and Precautions (5.1)].

Lactic Acidosis

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmia's. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL [see Warnings and Precautions (5.2)].

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.2)].

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.2), Drug Interactions (7), Use in Specific Populations (8.6, 8.7)].

If metformin-associated lactic acidosis is suspected, immediately discontinue pioglitazone and metformin hydrochloride and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.2)].

WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS

See full prescribing information for complete boxed warning.

Congestive Heart Failure

Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride, cause or exacerbate congestive heart failure in some patients. (5.1)

After initiation of pioglitazone and metformin hydrochloride, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If congestive heart failure develops while taking pioglitazone and metformin hydrochloride, consider discontinuation of pioglitazone and metformin hydrochloride or dosage reduction of pioglitazone in pioglitazone and metformin hydrochloride. (5.1)

Pioglitazone and metformin hydrochloride is not recommended in patients with symptomatic heart failure. (5.1)

Initiation of pioglitazone and metformin hydrochloride in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated. (4, 5.1)

Lactic Acidosis

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmia's. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL. (5.2)

Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high-risk groups are provided in the Full Prescribing Information. (5.2)

If lactic acidosis is suspected, discontinue pioglitazone and metformin hydrochloride and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.2)

Recent major changes (as listed on the label)

Boxed Warning 08/2026

Warnings and Precautions, Lactic Acidosis (5.2) 08/2026

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
2 approved generic applications on the market

Metformin / pioglitazone questions

How much does metformin / pioglitazone cost without insurance?

Pharmacies pay about $8.82 for 30 tablets of metformin / pioglitazone 500 mg / 15 mg tablet ($0.2940 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $20.64. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is metformin / pioglitazone in shortage?

No shortage is reported for metformin / pioglitazone right now. We check the national shortage list every day.

Has metformin / pioglitazone been recalled?

1 recall on record, none ongoing. Recalls name specific lots - check yours.

When did the metformin / pioglitazone label last change?

The official label was last updated on September 11, 2026 (version 15). See what changed.

Talk about metformin / pioglitazone

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.